Malignant hyperthermia in Czechia and Slovakia
| Autoři | |
|---|---|
| Rok publikování | 2022 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | British Journal of Anaesthesia |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.sciencedirect.com/science/article/abs/pii/S0007091222002422?via%3Dihub |
| Doi | http://dx.doi.org/10.1016/j.bja.2022.04.029 |
| Klíčová slova | Malignant hyperthermia; Czechia; Slovakia |
| Přiložené soubory | |
| Popis | Malignant hyperthermia (MH) is a rare, hereditary, life-threatening pharmacogenetic disorder triggered by some commonly used anaesthetics: all halogenated volatile anaesthetics and the depolarising neuromuscular blocking agent succinylcholine.1 Despite progress in common knowledge, diagnostics, and dantrolene availability, MH is still considered a severe anaesthetic complication. Genes pathogenically connected with MH include RYR1, CACNA1S, and STAC3.2 Prevalence of RYR1 variants associated with MH differs between countries and geographical areas.3 There is one MH diagnostic centre in the Slavic part of Europe located in Brno, Czechia that serves both Czech and Slovak patients. |
| Související projekty: |
|